Efficacy of low-dose 90Sr-90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas

Abstract

The aim of the present study was to investigate the clinical efficacy and safety of low-dose Sr-Y therapy combined with the topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas (IHs). A total of 72 infants with hemangiomas were allocated at random into the observation group (17 cases aged ≤3 months, 20 cases aged >3 months) or the control group (15 cases aged ≤3 months, 20 cases aged >3 months). The observation group was treated with low-dose Sr-Y combined with timolol, while the control group received an identical dose of Sr-Y with physiological saline. Data were collected for statistical analysis, and treatment efficacy was compared between the two groups. In the observation group, 100% (37/37) of subjects exhibited an 'excellent' response to the treatment, while 94.1% (16/17) of patients aged ≤3 months and 85.0% (17/20) aged >3 months were classed as being cured. In the control group, the treatment was classed as 'effective' in 100% (35/35) of the subjects, while the excellent response rate was 86.7% (13/15) among the infants aged ≤3 months and 75.0% (15/20) among the infants aged >3 months. The 'cure' rates in the control group were 66.7% (10/15) and 60.0% (12/20) for the ≤3-month- and >3-month-old subjects, respectively. The excellent response and cure rates were notably higher in the observation group than those in the control group. Comparison between the two groups revealed a χ value of 13.90 (P<0.01) for excellent responses in subjects aged ≤3 months, while for patients aged >3 months the χ value was 28.57 (P<0.01). Analysis of the cure responses gave similar results [≤3 months, χ=23.22 (P<0.01); >3 months, χ=15.67 (P<0.01)]. At 3-4 months after the first course of treatment, the cure rate was 33.3% (11/33) in the observation group, which was significantly higher than the rate of 18.32% (4/22) in the control group (χ=5.92, P<0.05). No serious adverse reactions were observed in either group. In summary, low-dose Sr-Y therapy combined with the topical application of 0.5% timolol maleate induces a rapid response in superficial IH, with excellent efficacy and no obvious adverse reactions, and may represent a clinically applicable intervention.

The Efficacy and Safety of Topical β-Blockers in Treating Infantile Hemangiomas: A Meta-Analysis Including 11 Randomized Controlled Trials

“…Eleven studies enrolling 1,235 infants with hemangiomas that met our inclusion criteria were included in our meta-analysis. Six [8][9][10][11][12][13] of 11 studies compared the efficacy and safety of a single topical β-blocker with other interventions (such as oral propranolol, placebo, corticosteroids, laser or radiation) in the treatment of SIH, and 5 [14][15][16][17][18] of 11 studies evaluated the efficacy and safety of a topical β-blocker when it was combined with another intervention in treating MIH. A flow diagram that illustrates the search process is shown in Figure 1.…”

Treatments for infantile Hemangioma: A systematic review and network meta-analysis

“…We read the full-text articles and excluded 56 articles not meeting the inclusion criteria or meeting the exclusion criteria (18 were non-RCTs; 11 without any endpoint we need; 7 without full-text; 7 letters; 5 single-arm study; 3 had duplicate content; 3 studies with patients treated before; 1 review; and 1 article's study design was not eligible). Moreover, treatments of Wu's (surgical resection and pingyangmycin) [11] , Jung's (soft X-ray radiation) [12] and Zhu's ( 90 Sr- 90 Y therapy) [13] could not be made indirect comparison with other studies, because they were the only ones who had studied the therapies, we excluded them. Eventually, 30 RCTs met the eligibility criteria for our study with an acceptable risk of bias among them.…”

“…We found that combined b blockers with laser might was superior to other treatments, regardless of age and type of IHs. ( 90 Sr-90 Y therapy) [13] could not be made indirect comparison with other studies, because they were the only ones who had studied the therapies, we excluded them. Eventually, 30 RCTs met the eligibility criteria for our study with an acceptable risk of bias among them.…”

Interventions for infantile haemangiomas of the skin: abridged Cochrane systematic review andGRADEassessments

“…The search results are shown in Figure . We included 28 studies reported in 37 references enrolling 1728 children . We assessed seven studies as awaiting classification because only partial information was available for these references (Appendix S2; see Supporting Information) .…”